Introduction
Chronic Inflammatory Demyelinating Polyneuropathy, often known as CIDP, is an autoimmune condition that is very uncommon and affects the peripheral nervous system. Numbness, tingling, weakness, and ultimately paralysis may be the outcome of this illness, which causes inflammation and destruction to the protective layer (myelin) surrounding nerve fibres. The symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP) often begin gradually and then steadily deteriorate with time(Svačina & Lehmann, 2022). CIDP commonly affects both sides of the body. Physical therapy is an effective treatment for controlling the symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP), even though the condition’s origin is unclear.
In the following paragraphs, we will talk about physical therapy’s impact on CIDP. After an introduction to the biology of chronic inflammatory demyelinating polyneuropathy (CIDP), we will next outline physical therapy as a potential treatment for CIDP. After that, we will go more into the precise methods and approaches that physical therapists employ to address the symptoms of CIDP. Some examples of these techniques and approaches include exercise, manual therapy, and electrical stimulation. In conclusion, we will go through the most recent findings from studies on the efficacy of physical therapy in treating CIDP and the possible implications these findings have for developing new treatment approaches.
Pathophysiology of CIDP
Demyelination and inflammation of the peripheral nerves are the results of CIDP, a chronic autoimmune illness. It is unclear what causes CIDP, although an aberrant immune response is a likely suspect(Fehmi et al., 2023). Myelin sheaths, which protect nerve fibres, are attacked by the immune system in persons with chronic inflammatory demyelinating polyneuropathy (CIDP). Because of this, myelin is damaged, which impedes or halts the conduction of nerve impulses. Numbness, tingling, weakness, and even paralysis may affect those with CIDP.
While the precise pathophysiology of CIDP is poorly known, researchers have identified several potential risk factors. Environmental variables, including exposure to chemicals or stress, genetic predisposition and viral infections, play a role.
Inflammation is a central underlying mechanism of CIDP. When the immune system attacks the myelin sheath, inflammatory cells, including T cells and macrophages, are sent to the scene. Myelin injury and the immunological response are exacerbated by the cytokines and other inflammatory mediators released by these cells. Long-term inflammation may cause irreversible nerve damage and a decrease in function.
Loss of nerve conduction velocity is also a key element in CIDP (NCV) pathophysiology. Nerve conduction velocity (NCV) is the rate at which signals move down an axon, and it plays a crucial role in how well nerves work. Demyelination of nerve fibres causes a slower NCV, which may cause symptoms including weakening and lack of sensation in persons with CIDP(Mirian et al., 2023). Paralysis or other loss of function may result from complete blockage of nerve fibres in extreme circumstances.
Consequently, aberrant nerve regeneration is also a hallmark of chronic inflammatory demyelinating polyneuropathy. The body strives to heal damaged neurons by creating new myelin and axons in response to inflammation and demyelination. Nevertheless, this procedure must sometimes be performed correctly, and defective nerve fibres emerge. Although the initial immune reaction is under control, these aberrant fibres may still contribute to CIDP symptoms.
Physical Therapy as a Treatment Option for CIDP
One treatment option for CIDP is called physical therapy, which entails using a variety of strategies to manage the symptoms of the illness. Physical therapy aims to assist patients in improving their overall quality of life and keeping their functional skills at a high level. The symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP) may be managed by physical therapists with a mix of exercises, manual treatment, and electrical stimulation.
One of the critical objectives of physical therapy, while the patient is being treated for CIDP is to preserve and even improve the patient’s level of muscle strength. Those who have chronic inflammatory demyelinating polyneuropathy (CIDP) gradually weaken their muscles due to damage to the nerves that control those muscles(Korinthenberg et al., 2021). Exercise is an essential component of the treatment plan for CIDP that is provided by physical therapy. This is because exercise helps to maintain muscular strength and prevents the loss of muscle mass. In addition, engaging in physical exercise helps to improve circulation and decrease inflammation, both of which may aid in the alleviation of symptoms associated with chronic inflammatory demyelinating polyneuropathy (CIDP).
In addition to manual treatment, physical therapy for CIDP may include additional techniques. Hands-on approaches are used to handle the soft tissues and joints of the body throughout this process. Manual therapy effectively reduces pain, enhances the range of motion, and makes muscles more flexible. Also, it may assist in improving circulation and reducing inflammation in the afflicted locations.
Another method used in the treatment of CIDP via physical therapy is electrical stimulation. The nerves and muscles may be stimulated by applying electrical currents via “electrical stimulation.” The afflicted regions may have less discomfort and inflammation due to this and increased muscular strength.
Specific Techniques Used in Physical Therapy for CIDP
In the treatment of CIDP, physical therapy makes use of several different particular strategies. These approaches are geared toward dealing with the specific difficulties and symptoms linked to the illness.
Progressive resistance training is one of the techniques that may be utilized in physical therapy to treat CIDP (PRT). Advanced resistance training, or PRT, is to progressively increase the amount of resistance the muscles are subjected to. PRT often includes the use of weights and resistance bands. This has the potential to assist in the enhancement of muscular strength as well as the prevention of muscle atrophy.
Stretching is another component of the physical treatment for CIDP that patients undergo. Stretching the afflicted muscles and joints may increase flexibility and range of motion in those regions. Since the disorder may cause stiffness and reduced movement in the afflicted muscles and joints, this might be of particular importance for those with CIDP. Stretching may also help lessen muscular spasms and cramping, typical symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP).
Manual therapy treatments, such as massage and myofascial release, benefit those suffering from chronic inflammatory demyelinating polyneuropathy (CIDP)(Craig, 2021). Myofascial release and massage both improve muscular flexibility and relieve tension that has built up in the muscle tissue. Massage may help to improve circulation and reduce inflammation in the affected areas, while myofascial release may help to improve muscular flexibility. These strategies can reduce some of the anguish and suffering associated with CIDP.
Electrical stimulation is yet another approach used in treating CIDP utilizing physical therapy. Transcutaneous electrical nerve stimulation (TENS), functional electrical stimulation (FES), and neuromuscular electrical stimulation are just some of the many different types of electrical stimulation that may be provided (NMES)(Carson & Buick, 2021). Although transcutaneous electrical nerve stimulation (TENS) uses low-level electrical impulses to reduce pain and improve circulation, functional electrical stimulation (FES) uses electrical stimulation to activate muscles that have either grown weak or paralyzed. The goal of neuromuscular electrical stimulation exercise, often known as NMES, is to improve the muscles’ strength and function by using electrical stimulation.
During the course of the treatment for CIDP that is offered by physical therapy, one of the modalities that may be used is water therapy. Participating in aquatic therapy, which consists of conducting exercises in a swimming pool, may provide those who suffer from chronic inflammatory demyelinating polyneuropathy (CIDP) with some degree of relief from their symptoms. The buoyancy of the water may aid in lessening the amount of stress exerted on the joints and muscles, making it simpler to complete exercises and enhancing mobility. This would make it easier to exercise overall. Exercising in water as opposed to on land may benefit the participant. Exercising in water may bring significant health advantages, and these are just a few examples.
Research on the Effectiveness of Physical Therapy for CIDP
The variety of the illness presents a difficulty to researchers who want to investigate the efficacy of physical therapy in treating CIDP. While CIDP may manifest itself in a wide variety of symptoms and illness courses, the individual patient’s reaction to physical therapy may also differ depending on the severity of their particular case(Singh et al., 2022). To find a solution to this problem, several researchers have concentrated their efforts on establishing personalized physical therapy regimens that can be adapted to meet the requirements of each unique patient.
The use of customized physical therapy for patients diagnosed with CIDP was investigated in a research published in the Journal of Neurological Sciences in 2021. According to the research findings (Van den Bergh et al., 2021), a specialized program consisting of strength training and stretching was successful in helping persons with CIDP improve their muscular strength, walking ability, and overall quality of life. The treatment plan was altered over time depending on how well the patient responded to the therapy, and it was meant to focus on treating certain muscle groups that were afflicted by the ailment.
Another area of research being conducted in physical therapy for CIDP focuses on the use of treatments based on technology. To improve the muscle function of those who suffer from chronic inflammatory demyelinating polyneuropathy, some researchers, for example, have studied electrical stimulation and neuromuscular re-education techniques (CIDP). A study(Brundin, n.d.) conducted in 2019 and published in the Journal of Clinical Neuromuscular Disease discovered that patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP) benefited from receiving electrical stimulation therapy in terms of their ability to improve their muscle strength and function. Based on this, it seems to be a practical addition to conventional physical therapy approaches.
In general, the data on the efficacy of physical therapy for CIDP is encouraging; nevertheless, further study is required to appreciate this therapeutic method’s possible advantages and limits fully. Physical therapy will continue to play an essential role in managing this complicated condition even as our understanding of the pathophysiology of CIDP improves and as new technologies and treatment strategies are developed. This is because CIDP management is a complex and challenging condition.
Complement activation in CIDP and potential therapeutic strategies
The participation of complement activation in the immune response is an aspect of the pathophysiology of CIDP that stands out as particularly noteworthy. The complement system is a set of proteins activated in the innate immune system in response to tissue injury or foreign invaders. This reaction may occur in either case. Complement activation has been linked to demyelination and nerve fibre loss in persons with chronic inflammatory demyelinating polyneuropathy (CIDP). More specifically, activation of the complement system produces membrane attack complexes (MACs) on the surface of myelin sheaths(Querol et al., 2022). These complexes are capable of causing damage to the myelin as well as an inflammatory response. From this information, one possible treatment approach for CIDP would be inhibiting complement activation.
In recent years, several complement-targeting medicines have been created to treat autoimmune illnesses like CIDP. These treatments have been examined in clinical studies to determine their efficacy. Eculizumab is a monoclonal antibody that targets the C5 component of the complement system. It is an example of one of these types of drugs. Those who had refractory CIDP had considerable improvements in their muscular strength and impairment after receiving therapy with eculizumab, according to research published in The Lancet Neurology in 2013(Klotz & Wiendl, 2013). While further study is required to fully understand the potential advantages and hazards of complement-targeting therapy for CIDP, this strategy provides a promising option for future research and development. CIDP is an autoimmune disease that affects the central nervous system.
Targeting complement activation in the immunological response to CIDP is an exciting and potentially fruitful direction for future study. In persons with chronic inflammatory demyelinating polyneuropathy (CIDP), complement activation has been linked to demyelination and the loss of nerve fibres. Drugs that target complement components have shown promise in therapeutic studies. An exciting and potentially fruitful line of investigation for treating CIDP is the creation of medicines that target complement.
Conclusion
In conclusion, CIDP is a complicated condition that calls for a treatment strategy incorporating various components. Physical therapy is one treatment that has shown potential in controlling the symptoms of chronic inflammatory demyelinating polyneuropathy (CIDP) and increasing the quality of life for persons who have the illness. Nevertheless, further study is required to completely comprehend the optimum window of time, length of treatment, and specific procedures for physical therapy treatments. Also, targeting complement activation in the immunological response to CIDP is a potential field of study for developing innovative treatment techniques. This is because complement is involved in the immune response. In the end, further investigation into the etiology and therapy of CIDP is necessary to improve outcomes for those coping with this challenging illness.
Reference
Brundin, P. (n.d.). WCN19 Journal Invited Speakers_V1.
Carson, R. G., & Buick, A. R. (2021). Neuromuscular electrical stimulation-promoted plasticity of the human brain. The Journal of Physiology, 599(9), 2375–2399.
Craig, A. (2021). Neuropathies. In Braddom’s Physical Medicine and Rehabilitation (pp. 842–874). Elsevier.
Fehmi, J., Davies, A. J., Antonelou, M., Keddie, S., Pikkupeura, S., Querol, L., Delmont, E., Cortese, A., Franciotta, D., & Persson, S. (2023). Contactin-1 links autoimmune neuropathy and membranous glomerulonephritis. Plos One, 18(3), e0281156.
Klotz, L., & Wiendl, H. (2013). Monoclonal antibodies in neuroinflammatory diseases. Expert Opinion on Biological Therapy, 13(6), 831–846.
Korinthenberg, R., Trollmann, R., Plecko, B., Stettner, G. M., Blankenburg, M., Weis, J., Schoser, B., Müller-Felber, W., Lochbuehler, N., & Hahn, G. (2021). Differential Diagnosis of Acquired and Hereditary Neuropathies in Children and Adolescents—Consensus-Based Practice Guidelines. Children, 8(8), 687.
Mirian, A., Aljohani, Z., Grushka, D., & Florendo-Cumbermack, A. (2023). Diagnosis and management of patients with polyneuropathy. CMAJ, 195(6), E227–E233.
Querol, L. A., Hartung, H.-P., Lewis, R. A., van Doorn, P. A., Hammond, T. R., Atassi, N., Alonso-Alonso, M., & Dalakas, M. C. (2022). The role of the complement system in chronic inflammatory demyelinating polyneuropathy: Implications for complement-targeted therapies. Neurotherapeutics, 19(3), 864–873.
Singh, N., Hamid, K., Goel, Y., Singh, L., & Pandey, R. K. (2022). A review on diabetic neuropathy (DN): Classification, Diagnosis, Management, and its treatments. NeuroQuantology, 20(15), 3519–3539.
Svačina, M. K., & Lehmann, H. C. (2022). Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Current Therapies and Future Approaches. Current Pharmaceutical Design, 28(11), 854–862.
Van den Bergh, P. Y., van Doorn, P. A., Hadden, R. D., Avau, B., Vankrunkelsven, P., Allen, J. A., Attarian, S., Blomkwist-Markens, P. H., Cornblath, D. R., & Eftimov, F. (2021). European Academy of Neurology/Peripheral Nerve Society guideline on diagnosing and treating chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision. Journal of the Peripheral Nervous System, 26(3), 242–268.
write